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■ EDITORIAL ■
Fertility preservation for women with malignancy has
recently gained importance for the following reasons.
First, malignant diseases are not rare in women of re-
productive age [1]. Second, progress in cancer treat-
ment has markedly improved the survival rates of these
patients. Third, conservative surgery in the management
of cancers of the female reproductive organs (organ-
preserving surgery) has become more acceptable.
Fourth, the use of preoperative or postoperative radio-
therapy or chemotherapy might directly or indirectly af-
fect ovarian function, although the direct mechanisms of
chemotherapy-induced ovarian failure are poorly un-
derstood. Visualization of end in vivo chemotherapeutic
damage to human oocytes is practical at autopsy or
after the completion of treatment [2]. Fifth, because of
the recent trend toward delayed pregnancy [3–6], an in-
creasing number of patients may request preservation of
future fertility. There is still no consensus on the optimal
therapeutic approach with which to manage patients
with cancer who wish to preserve their fertility. Further-
more, the number of women diagnosed with cancer-
related diseases and who wish to maintain their future
reproductive function is increasing. Therefore, this raises
the question, how can the cytotoxicity of therapy on the
gonads of these female cancer patients be reduced?
In fact, ovarian damage and failure is an important
and, unfortunately, common long-term side effect of
curative chemotherapy [2]. Sterilization and early men-
opause in young female adults have a high-level impact
on patient self-esteem and quality of life, as in the case
reported by Lee and Pan in this issue [7]. The patient
lost her interest in sexual activity when she was diag-
nosed with cancer, even though she was informed that
she had been cured by chemotherapy. Unfortunately,
the prospect of ovarian failure and impaired fertility
after antineoplastic therapy is a difficult topic for
patients and clinicians to deal with because of the lack
of good prognostic information. The frequency of ovar-
ian failure varies with factors such as the type, dose,
duration of chemotherapy treatment, and age of the
patient [2]. There are currently no reliable estimates for
the magnitude of risk associated with these parameters,
because acute ovarian failure can occur during or shortly
after the completion of irradiation or chemotherapy and
may be transient or permanent. In contrast, premature
ovarian failure or premature menopause typically man-
ifests after a post-treatment return of regular menses
with subsequent loss of ovarian function before the age
of 40 years [8]. Therefore, any agent that might provide
potential benefits in protecting the ovarian function of
women with cancer who were treated with cytotoxic
drugs or radiation is welcome. We wish to update recent
knowledge regarding this serious topic.
First, modern techniques to prevent treatment-
induced ovarian ablation include better shielding of the
ovaries from the damaging effects of radiation. This can
be accomplished by implementing transposition proce-
dures to move the ovaries outside of the area at risk [8].
Second, embryo cryopreservation is an established clini-
cal procedure after in vitro fertilization and is currently
the only widely available option for fertility preservation
in female patients who need chemotherapy or radio-
therapy [1]. Third, oocyte cryopreservation is an exper-
imental option for female fertility preservation that can
be offered to unmarried cancer patients with no male
partner or to those who do not wish to use a sperm
donor [1]. Fourth, unlike embryo or oocyte cryop-
reservation, hundreds of primordial follicles containing
immature oocytes may be cryopreserved without the
need for ovarian stimulation and the resulting delay in
initiating cancer treatment. Ovarian cryopreservation
and transplantation is an exciting but still experimental
possibility for fertility preservation in women. Fifth, the
use of pharmacologic prevention, e.g. gonadotropin-
releasing hormone (GnRH) agonist as a co-treatment for
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chemotherapy, is still in the experimental stage. Com-
pared with GnRH, GnRH agonists have a longer half-life
and elicit prolonged continuous activation of the GnRH
receptor. Downregulation of the GnRH receptor results
in a decreased level of gonadotropin and suppressed
production of ovarian hormones [9]. This hypothesis was
based on the initial reports that erroneously concluded
that pediatric patients were immune to the gonadal-
damaging effects of chemotherapy [10]. GnRH agonist
co-treatment for the prevention of chemotherapy-
induced gonadotoxicity should only be offered to
patients after obtaining informed consent from an
institutional review board-approved investigational
protocol, because the effectiveness of GnRH agonists as
fertility-preserving agents is still debatable [10,11]. 
A thorough literature search has found conflicting
data regarding the effectiveness of GnRH agonist co-
treatment in protecting the ovary from the damage of
chemotherapy [12,13].
Based on the report by Pan and Lee [7], we should
take more care with and pay more attention to younger
patients with cancer who wish to preserve their future
fertility, even though they can be successfully cured by
multimodal antineoplastic treatments.
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